Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateNew HampshireIn Committee
HB 1755: relative to the 340B discounted drug purchasing program.
Yury Polozov
HB 1755 status: In Committee — Subcommittee Work Session: 09/23/2026 09:30 am GP 230 (updated Sep 17, 2026).
Source
LegiScan
Confidence
High
Analysis basis
LegiScan full bill text
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
66OUT OF 100
Score:66/100 civic fit
Risk:Moderate Risk
Impact:Moderate Impact 65/100
Constitutionality85%
Bipartisan50%
Public opinion70%
Bill summary
What changes
The bill creates new reporting mandates for 340B covered entities, requiring them to submit extensive data on finances, charity care, pharmacy contracts, and collection practices to the DHHS and the Department of Justice.
Who is affected
340B covered entities (hospitals and offsite outpatient facilities) operating in New Hampshire, the Department of Justice (Charitable Trusts Unit), and the Department of Health and Human Services.
Requirements and enforcement
Covered entities must report annual aggregate drug costs, savings usage, charity care policies, and collection practices. The Director of Charitable Trusts must review this data for compliance with charitable obligations.
Costs and funding
The Department of Justice estimates $398,000 in annual personnel costs. Covered entities face significant compliance and administrative costs.
When it takes effect
Reporting requirements begin in 2027 based on 2026 data. Effective date is January 1, 2027.
Potential benefits
Increased transparency, potential for greater reinvestment in community healthcare, and improved accountability for non-profit entities.
Risks and tradeoffs
Compliance costs, risk of heavy fines, potential for regulatory misalignment with federal law, and the risk that increased administrative pressure may negatively impact patient services.
What is still unknown
The specific costs for the Department of Health and Human Services and the final impact on facility participation in the 340B program.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Mixed / Neutral
55%
Benefits
- Increases transparency on the use of federal drug discount savings
- Encourages alignment of hospital operations with charitable missions
- Provides data to help assess the effectiveness of local healthcare subsidies
Risks
- Significant administrative compliance costs for 340B covered entities
- Potential risk of state-level penalties affecting operational viability
- Increased state expenditures for Attorney General staffing and oversight
Society
Positive outlook
70%
Benefits
- Aims to ensure savings are reinvested into charity care for indigent populations
- Increases scrutiny on aggressive collection practices against low-income patients
- Promotes broader availability of sliding fee scales
Risks
- May discourage hospitals from serving high-risk populations if compliance is too strict
- Does not mandate specific levels of charity care spending
- Risk that intense regulation could lead some facilities to reduce service availability
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Positive outlook
80%
Benefits
- Requires reporting of aggregate 340B program data to the legislature
- Grants the Director of Charitable Trusts explicit authority to review 340B compliance
- Establishes a clear enforcement pathway for charitable non-compliance
Risks
- Data submitted by entities is kept confidential from the public
- Enforcement relies heavily on the interpretation of 'bona fide charitable purpose'
- Reporting requirements create potential for regulatory overreach
Public Health & Safety
Positive outlook
60%
Benefits
- Promotes better data on how 340B savings support indigent health care
- Protects access to essential medicines by discouraging excessive patient collections
- Ensures health safety nets align with documented community needs
Risks
- Compliance burdens could strain the operational capacity of safety-net providers
- Focus on for-profit/non-profit status may distract from direct clinical care delivery
- Potential for hospitals to exit the 340B program to avoid new regulatory burdens
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
LegiScan
Official bill text or data from LegiScan.
Confidence
High
Information is complete and verified.
Analysis basis
LegiScan full bill text
Source used for this bill's analysis.
Source note
The bill imposes significant new personnel and financial costs on the Department of Justice for oversight enforcement.
Analysis scope
Fiscal note remains incomplete pending DHHS cost estimates
04
Where it stands
Official record- IntroducedComplete
- CommitteeCurrent
- Chamber votesUpcoming
- Final agreementUpcoming
- GovernorUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.